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ABSTRACT
Retinoic acid receptors (RARs) a, b and c are
key regulators of embryonic development.
Hematopoietic differentiation is regulated by RARa,
and several types of leukemia show aberrant RARa
activity. Through microarray expression analysis,
we identified transcripts differentially expressed
between F9 wild-type (Wt) and RARa knockout
cells cultured in the absence or presence of the
RAR-specific ligand all trans retinoic acid (RA). We
validated the decreased Mest, Tex13, Gab1, Bcl11a,
Tcfap2a and HMGcs1 transcript levels, and
increased Slc38a4, Stmn2, RpL39l, Ref2L, Mobp
and Rlf1 transcript levels in the RARa knockout
cells. The decreased Mest and Tex13 transcript
levels were associated with increased promoter
CpG-island methylation and increased repressive
histone modifications (H3K9me3) in RARa
knockout cells. Increased Slc38a4 and Stmn2 tran-
script levels were associated with decreased
promoter CpG-island methylation and increased
permissive histone modifications (H3K9/K14ac,
H3K4me3) in RARa knockout cells. We demon-
strated specific association of RARa and RXRa
with the Mest promoter. Importantly, stable expres-
sion of a dominant negative, oncogenic PML–RARa
fusion protein in F9 Wt cells recapitulated the
decreased Mest transcript levels observed in RARa
knockout cells. We propose that RARa plays an im-
portant role in cellular memory and imprinting by
regulating the CpG methylation status of specific
promoter regions.
INTRODUCTION
Retinoic acid (RA) receptors a, b and g are nuclear recep-
tors that function as ligand-activated regulators of embry-
onic development. Retinoic acid receptor a (RARa) is the
major RA receptor involved in hematopoietic differenti-
ation (1). In vitro, RARa was shown to regulate the tran-
scriptional activities of RA target genes by dimerizing with
retinoid X receptors (RXRs) and binding to retinoic acid
response elements (RAREs) (2,3), but little is known
about transcriptional regulation by endogenous RARa.
Translocation events targeting the RARa gene is a
recurring theme in acute promyelocytic leukemia (APL)
(4–6), thus pointing to oncogenic functions of the resulting
RARa fusion proteins. The most common translocation
generates a PML–RARa fusion protein which is sufﬁcient
to induce APL in mouse models (7). The expression of
leukemic RARa fusion proteins attenuates the transcrip-
tional induction by RA (2,4) and induces DNA
hypermethylation of speciﬁc genes (8). Importantly,
aberrant promoter methylation is a key feature in APL
patients (9,10). The deregulated promoter methylation in
cells from APL patients and the binding of RARa to
genomic regions devoid of RA inducible genes (11,12)
strongly argue for a role of RARa in regulating cellular
memory and imprinting through CpG methylation of
promoter regions.
The nuclear receptor co-regulatory protein TIF1a
(Trim24) modulates the function of RARa in a
ligand-dependent manner, and loss of TIF1a increases
the incidence of hepatocellular carcinomas in animal
models (13), indicating that unmodulated RARa activity
in certain contexts can drive tumorigenesis. Studies from
MMTV-wnt1 animal models demonstrated that agonist
activated RARa inhibited mammary tumor formation
and growth, but that the loss of RARa delayed
mammary tumorigenesis (14), thus supporting roles of
RARa as both a tumor suppressor and protooncogene.
Current models of nuclear receptor action suggest that
the different functions of RARa are dictated by cofactor
recruitment, resulting in epigenetic changes, e.g. histone
modiﬁcations (15).
Histone modiﬁcations are important hallmarks of epi-
genetic activity. Acetylation of histone 3 lysines 9 and 14
(H3K9/K14ac) and trimethylation of histone 3 lysine 4
(H3K4me3) are frequently increased in the promoter
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silenced genes (16,17). In contrast, trimethylation of
histone 3 lysine 9 (H3K9me3) is associated with imprint-
ing and transcriptional repression (16,18). H3K9me3 also
marks genes differentially expressed in human cancers
(19). The inverse relationship between H3K4me3 and
H3K9me3 is emphasized by the observation that HP1, a
key factor in the formation of heterochromatin, binds with
high afﬁnity to histone H3 methylated at lysine 9 but not
at lysine 4 (18). Consequently, the transcriptional status is
reﬂected by various epigenetic marks.
The heritable silencing and imprinted regulation of
mammalian transcription relies in part on the symmetric
methylation of CpG dinucleotides (20). In humans, im-
printing defects have been associated with Beckwith-
Wiedemann, Prader-Willi and Angelman syndromes
(21,22). The processes of hypermethylation and de novo
DNA methylation have been extensively studied in devel-
opment as well as in cancer, but less is known about the
role of DNA demethylation (23). This may be because
enzymes catalyzing the active removal of cytosine methy-
lation have not been identiﬁed, and because appropriate
model systems have not been established (24). As a con-
sequence, it is not clear how speciﬁc promoters are
targeted for methylation or demethylation.
The F9 embryonal carcinoma stem cell system is a
well-established model for RA signaling (25).
Importantly, F9 cells are genomically stable and closely
resemble embryonic stem cells in morphology, growth
behavior and marker expression (25,26). We show here
that in F9 cells the knockout of RARa is associated
with reduced Mest transcript levels and gene-speciﬁc epi-
genetic changes in the Mest promoter region, an effect that
is partially rescued by restoring RARa2 expression.
Furthermore, a similar decrease in Mest transcript level
can be seen by overexpression of the dominant negative
PML–RARa oncoprotein. Our ﬁndings demonstrate that
the loss of a single transcription factor can induce exten-
sive, gene-speciﬁc changes in DNA methylation and thus
alter the epigenetic signature of the cell. Our ﬁndings yield
new insights into the mechanisms of APL and hereditary
disorders resulting from defective genetic imprinting. We
conclude that in F9 stem cells RARa sustains the tran-
scription of Mest and Tex13 and prevents the transcrip-
tion of Slc38a4 and Stmn2 by maintaining promoter
speciﬁc epigenetic signatures independent of the RA
ligand.
MATERIALS AND METHODS
Cell culture and RA treatment of F9 teratocarcinoma cells
F9 Wt and RARa
 /  cells were propagated as described
(27,28). A batch of F9 RARa
 /  cells with low passage
number was revived from liquid nitrogen cryo-storage and
the genotype of the RARa
 /  cell line was conﬁrmed by
western blot (Figure 1F). For microarray analyses
2.0 10
6 cells were plated 16h prior to drug treatment.
All-trans RA (Cat. #R2625, Sigma, MD, USA) and
cycloheximide (chx) (Cat. #C7698, Sigma, MD, USA)
were dissolved in 100% ethanol (EtOH). The cells were
pretreated with 1mg/ml chx for 30min before 7.5h treat-
ment with RA (1mM) or vehicle (EtOH, 0.1%). For gene
expression analyses F9 cells were cultured in RA (1mM) or
vehicle (0.1%, EtOH) 24 or 8h prior to RNA harvest.
Puriﬁcation of RNA, microarray analysis and statistical
analysis
Total RNA was extracted and on-column DNase treat-
ment was carried out using a RNAeasy mini kit (Cat.
#74104, Qiagen, MD, USA) according to the manufactur-
ers’ speciﬁcations. Preparation of cRNA, gel electrophor-
esis quality control, chip hybridization and scanning were
carried out by the Microarray Core Facility at Weill
Cornell Medical College (WCMC). The microarray
analyses were performed following the Affymetrix
Genechip expression analysis technical manual. The frag-
mented cRNA was hybridized to the microarray chips
(MG-430.2, Cat. #900496, Affymetrix, CA, USA), which
include over 45000 transcripts representing 34000
substantiated mouse genes. The hybridization assays
were performed using biological triplicates (e.g. independ-
ently propagated cells). The data were analyzed using
Genespring v7.0 software (Agilent Technologies, CA,
USA). Brieﬂy, the data sets were summarized using the
GC-RMA algorithm, followed by a three-step normaliza-
tion process consisting of: (i) data transformation, con-
verting values <0.01–0.01, (ii) chip normalization to the
50th percentile of total intensity and (iii) per gene normal-
ization to median intensity. Genes were ﬁltered by expres-
sion level to exclude genes with a raw signal below 100. In
order to identify RA-induced genes that were differentially
expressed between Wt and RARa
 /  cell line, treatment
(RA+chx) versus control (EtOH+chx) comparisons were
performed for each cell line. To determine which genes
were differentially expressed at statistically signiﬁcant
levels between EtOH- and RA-treated cells, a one-way
ANOVA (P<0.05 cutoff) was performed on each of the
two groups (Wt and RARa
 /  cells). To identify genes
which were differentially expressed between Wt and
RARa
 /  cell lines independent of RA treatment, Wt
versus RARa
 /  cell line comparisons were performed
for each of the two conditions (RA+chx and vehicle+chx),
and a one-way ANOVA (P<0.05 cutoff) was performed
on each of the two groups (EtOH and RA-treated cells).
The data have been deposited in the GEO database (ac-
cession #GSE31280). For reverse transcriptase (RT) reac-
tions total RNA was extracted using Trizol reagent (Cat.
#15596, Invitrogen, CA, USA). The RNA was quantitated
by optical density at 260nm.
Generation of cDNA, semi-quantitative and real-time
PCR reaction
Total RNA (1.5mg) isolated from F9 cells was reverse
transcribed (Cat. #95048, Quanta Biosciences, MD,
USA), then diluted 1:10 with H2O. Subsequent PCR reac-
tions were set up using 3–5ml as template.
Semi-quantitative PCRs were performed with Taq poly-
merase (0.5U, Cat. #CB4050, Denville Scientiﬁc, NJ,
USA) in a BioRad iCycler: (95 C, 120s) 1, (94 C, 15s;
55–65 C, 30s; 72 C, 30s) 28–35, (72 C, 4min) 1.
Nucleic AcidsResearch, 2012, Vol.40,No. 1 103Annealing temperature and number of repeats were
determined empirically for each primer pair such that
the PCR was in the linear range. Ampliﬁcation in the
linear range was demonstrated by including a 3-fold
serial dilution of cDNA from RA-treated Wt cells in
each reaction (1:1, 1:3, 1:9). An RT reaction without RT
enzyme served as negative controls for gDNA template.
The PCR products were subjected to electrophoresis on
TAE gels with 1.5% (w/v) agarose and 0.3mg/ml ethidium
bromide. The bands were visualized and quantiﬁed using a
FluorChem 8800 system (Alpha Innotech, CA). Real-time
PCR was performed using SYBR Green Supermix (Cat.
#84091, Quanta Biosciences, MD, USA) in a 15ml
reaction containing reaction-mix ( 1), 0.25mM of each
primer and 3ml of cDNA template. The reactions were
run on a Bio-Rad MyiQ
TM Single Color Real-time PCR
Detection System (BioRad, CA, USA). Ampliﬁcation in
the linear range was demonstrated by a serial dilution of
cDNA from RA-treated Wt cells included in each reaction
(1:1, 1:5, 1:10, 1:50, 1:100, 1:500). Reactions with H2O and
template without RT enzyme, respectively, served as
negative controls for primer–dimer and for ampliﬁcation
Figure 1. Gene expression analyses of wild-type and RARa knockout cells. Relative transcript levels were identiﬁed by microarray analysis and the
genes differentially expressed (2-fold or more difference in transcript levels between wild-type and RARa knockout cells) were plotted as fold
difference in presence of RA against the fold difference in vehicle-treated cells (A right panel, transcript levels in RARa
 /  cells >2-fold transcript
levels in Wt cells; C left panel, transcript levels in RARa
 /  cells <0.5-fold transcript levels in Wt cells). Selected genes with increased transcript
levels in RARa
 /  cells (Slc38a4 and Stmn2) and with decreased transcript levels in RARa
 /  cells (Mest and Tex13) were validated by real-time
PCR (A left panel and C right panel, respectively) to be differentially expressed between Wt and RARa
 /  cells in a ligand-independent manner
(measured in arbitrary units correlated with 36B4 expression, note the logarithmic scale). The duration of the RA treatment is indicated by the bar
color (0h; gray, 8h; light gray, and 24h; dark gray). Additional genes were validated by semi-quantitative PCR to be differentially expressed between
Wt and RARa
 /  cells in a ligand-independent manner. Genes with increased transcript levels (B) and genes decreased transcript levels (D). Different
time points of RA treatment are indicated by the bar color (0h; gray, and 24h; dark gray). The speciﬁc bands (white arrowheads) and the relative
transcript levels (bars above gels) are indicated. Assessment of household gene (36B4 and HPRT1) transcript levels conﬁrmed similar amounts of
cDNA in all samples (data not shown). (E) Transcript levels of RA inducible genes (Cyp26a1, Hoxa5, Hoxb5 and Hoxb2) assessed by real-time PCR
at 0, 8 and 24h of RA treatment of Wt and RARa
 /  cells (correlated with 36B4 transcript levels). Each graph is a compilation of three independent
biological replicates. (F) Western blot validation of the RARa knockout cell line. A band of the expected size is detected by an RARa speciﬁc
antibody in Wt, but not in the RARa
 /  cell line (left). In lysates from transfected COS cells RARa, but not RARb or RARg, is detected by the Ab
(Santa Cruz, sc-551). The data represent three independent assays (microarray and real-time PCR), harvesting new RNA for each experiment, or a
representative assay out of at least three independent assays (semi-quantitative PCR and western blot).
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listed in the Supplementary Appendix S1A. Each expres-
sion analysis was performed using biological triplicates
(e.g. independently propagated cells, repeated three times).
Puriﬁcation of gDNA and Bisulﬁte methylation assay
gDNA was isolated from untreated F9 Wt and RARa
 / 
cells and puriﬁed (29,30). Promoter-speciﬁc methylation
was assessed by bisulﬁte sequencing (31). The regions
assayed were Mest:  337; +116, Slc38a4:  123; +374,
Stmn2:  103; +224, Tex13:  248; +29 and Cyp26a1:
 67; +152 relative to the transcriptional start site of
each gene, see Supplementary Appendix S1A for details
(Supplementary Data). In brief, cytosine to uracil conver-
sion was performed on 1.0mg of gDNA according to the
manufacturer (Cat. #D5001, Zymo Research, CA, USA).
PCR reactions were performed on the converted DNA
with promoter-speciﬁc primers (Supplementary Data)
designed using the online Methprimer software (32).
PCR reactions were set up using 3–5ml cytosine to uracil
converted gDNA as template with Taq polymerase (Cat.
#10342, Invitrogen, CA, USA) in 15ml reactions contain-
ing PCR buffer [ﬁnal concentration of 20mM Tris–HCl
(pH 8.4), 50mM KCl, 1.5mM MgCl2], 0.2mM concen-
tration of each deoxynucleoside triphosphate, 0.2mM con-
centration of each primer, and 3–5ml of cDNA template.
Sequential PCR reactions were performed using converted
gDNA (3–5ml), and then 1ml of the initial PCR, as tem-
plates in a BioRad iCycler using following protocol:
(95 C, 120s) 1, (94 C, 15s; 55 C, 30s; 72 C, 30s) 35–40,
(72 C, 4min) 1. In the second PCR reaction, semi-nested
primer pairs were utilized for increased ﬁdelity in the amp-
liﬁcation of Mest and Stmn2 promoter region. The PCR
products were puriﬁed using PCR puriﬁcation kit (Cat. #
28106, Qiagen, MD, USA), and the eluted DNA was re-
covered by ligation into the pGEM-T easy vector (Cat.
#A1360, Promega, WI, USA). The ligated products were
transformed into competent DH5a bacteria, and plated on
LB agar plates containing ampicillin for overnight incu-
bation at 37 C. DNA was isolated from resistant colonies
and conﬁrmed by NotI restriction digest (Cat. #R0189,
New England Biolabs, MA, USA) to contain inserts of
the expected sizes. From each F9 cell line (Wt and
RARa
 / ) a total of 10n independent clones containing
each of the desired PCR products were sequenced using
T7(+) and SP6(+) primers (Supplementary Data).
Western blots
The SDS–PAGE and western blot analysis were per-
formed as described (30,33) using RARa primary Ab
(Cat. #sc-551, Santa Cruz, CA, USA) in a 1:1000
dilution and HPR-conjugated anti-rabbit secondary Ab
(Cat. #sc-2030, Santa Cruz, CA, USA) in a 1:10000
dilution. Each Ab was diluted in PBS with 5% Blotto
(Biorad, CA, USA) and 0.1% Tween-20. The membranes
were developed with Supersignal Substrate (Cat. #34080,
Pierce, IL, USA) for 5min and exposed to Biomax ﬁlm
(Eastman Kodak, NY, USA).
Chromatin immunoprecipitation assays
A one-step ChIP protocol which utilizes formaldehyde
cross-linking was employed for histone ChIP assays. For
transcription factor ChIP assays (RARa and RXRa), we
used a two-step ChIP protocol. IPs of sonicated chromatin
from 5.0 10
6 F9 cells were performed with 2mg of Ab per
IP (30,31). The regions ampliﬁed were Mest:  337;  197,
Slc38a4:  123; +171, Stmn2:  103; +22, Tex13:  132;
+32 and Cyp26a1:  97;  10 relative to the transcriptional
start site of each gene (Supplementary Data). Each ChIP
assay was performed using biological triplicates (e.g. inde-
pendently propagated cells). Abs: H3K9me3 (ab8898,
Abcam, MA, USA), H3K4me3 (07-473, Upstate, MA,
USA), H3K9/K14ac (06-599, Upstate, MA, USA),
RARa (sc-551, Santa Cruz, CA, USA), RXRa (sc-553,
Santa Cruz, CA, USA), Rabbit-IgG (sc-2027, Santa
Cruz, CA, USA).
Generation of stable clones
The pSG5 mRARa2 and pSG5 mPML–RARa expression
vectors were stably introduced into F9 Wt and RARa
 / 
cells, respectively (Supplementary Data). In brief, the ex-
pression vector and a selection vector, pPGK Hygromycin
(34), were co-transfected into F9 cells using
lipofectamine2000 (Cat. #11668, Invitrogen, CA, USA)
as described (35). Colonies were picked and screened
(28). PCR screening was performed using the
mRARaE6(+)/mRARaE7( ) primer pair. Successful
gDNA puriﬁcation was evident by a 414-bp PCR
product, whereas integration of the transgene was
evident by an additional PCR product of 239bp.
Transgene expression in positive clones was veriﬁed by
the presence of a 162-bp PCR product using the
rb-globin50C/rb-globin30B primer pair, which spans the
b-globin intron of the pSG5 vector (primer sequences
(Supplementary Data)).
Accession of data sets
Gene expression proﬁles were deposited at GEO with
the accession code GSE31280 (http://www.ncbi.nlm.nih.
gov/geo/querry/acc.cgi?acc=GSE31280).
Statistical analysis
Biological triplicates were analyzed using one-way
ANOVA in the expression and ChIP analyses. The data
was analyzed by a two step approach; the ﬁrst step
assessed the effect of RA (vehicle versus RA-treated
cells). The second step assessed the effect of RARa (Wt
versus RARa
 /  cells). If the difference between vehicle
and RA-treated cells (ﬁrst step) was not signiﬁcant the
data was collectively assessed when assessing the effect
of the genotype (second step). The standard deviation
was determined for each of the data sets (plotted as
error bars in the graphs), and ANOVA values of
P<0.05 between compared samples were assigned statis-
tical signiﬁcance.
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Transcriptome proﬁling of F9 Wt and RARa knockout
cells reveals a ligand-independent role of RARa
We aimed to identify novel genes whose expression
depends on RARa. Therefore, we performed a compara-
tive microarray analysis of F9 Wt and F9 RARa
knockout (RARa
 / ) cells cultured in the presence or
absence of RA. Through pair-wise comparison between
the Wt and RARa
 /  cell lines in either the presence or
absence of RA (see supplementary material for details
(Supplementary Data)), we identiﬁed several genes that
were differentially expressed (Figure 1A and C display
genes increased and decreased, respectively, in RARa
 / 
relative to Wt cells). Excluding multiple hits of the same
genes, we found 63 transcripts with elevated levels in
RARa
 /  cells and 14 transcripts with reduced levels in
RARa
 /  cells relative to levels in Wt cells.
We reviewed the functions of the differentially ex-
pressed genes to elucidate the pathways in which RARa
may be implicated. Slc38a4 (solute carrier family 38,
member 4; Ata3) is a paternally expressed gene regulated
by imprinting (36). Slc38a4 encodes an arginine transport-
er found in placental tissue and in adult liver and muscle
(37). Stmn2 (Statmin 2; Scg10) is differentially expressed
during neoplastic conversion of human prostate epithelial
cells and may be an early marker of cancer initiation (38).
Ref2L (similar to RNA and export factor-binding protein
1–II) may, by similarity to Thoc4, function as a co-factor
for PML (39). RpL39l (ribosomal protein L39-like) is
involved in spermatogenesis and the human homolog is
overexpressed in various types of cancer, including
ovarian cancer (40). Mobp (myelin-associated
oligodendrocytic basic protein) stabilizes the myelin
sheath (41). Rlf (rearranged L-myc fusion sequence) is
the intrachromosomal recipient of the L-myc rearrange-
ment. Expression of the resulting fusion protein inhibits
embryonic stem cell differentiation and embryoid body
formation (42).
Mest (mesoderm speciﬁc transcript; Peg1) is a pater-
nally expressed gene regulated by imprinting; the Mest
promoter is unmethylated in sperm, but highly methylated
in oocytes (43,44). Decreased Mest expression has been
associated with glioblastoma (45), whereas invasive
breast and lung cancer show increased Mest expression
(46). Tex13 (testis expressed gene 13B) is located on the
X chromosome and may play a role in spermatogenesis
(47). Gab1 (growth factor receptor-bound protein 2
associated protein 1) is a key factor in endothelial devel-
opment (48). Tcfap2a (transcription factor AP-2, alpha) is
induced during RA-mediated differentiation of primary
astrocytes (49). Abnormal expression of the human
homolog was reported in breast cancer, acute lympho-
blastic leukemia, and head and neck squamous cell carcin-
omas (50–52). HMGcs1 (3-hydroxy-3-methylglutaryl-CoA
synthase 1) is involved in cholesterol biosynthesis (53).
The genes that are differentially expressed between Wt
and RARa
 /  cells are predominantly expressed in the
placenta, in the brain and in the testis (Supplementary
Data). These are tissues where imprinting plays a major
role in transcriptional regulation (54,55) thus suggesting
that RARa could be involved in regulating genetic
imprinting.
We veriﬁed transcript levels of a subset of the differen-
tially expressed genes identiﬁed in our microarray
analysis. The Slc38a4 and Stmn2 transcript levels were
assessed by real-time PCR upon 0, 8 and 24h of RA treat-
ment (Figure 1A, left panel). Relative to F9 Wt cells the
RARa
 /  cells exhibited increased levels of Slc38a4 and
Stmn2 at all three time points. The observed increases in
transcript levels of Ref2L, Rlf, RpL39l and Mobp in
RARa
 /  cells relative to Wt cells were validated by
semi-quantitative PCR (Figure 1B). The decreased Mest
and Tex13 transcript levels in RARa
 /  cells relative to
F9 Wt cells were validated by real-time PCR after 0, 8 and
24h of RA treatment (Figure 1C). The observed decreases
in Bcl11a, Gab1, HMGcs1 and Tcfap2a transcript levels in
RARa
 /  cells relative to Wt cells were validated by
semi-quantitative PCR (Figure 1B). Consistent with the
microarray data, the transcript levels were affected by
the knockout of RARa, but were relatively insensitive
to RA.
The transcript levels of 11 out of 12 differentially ex-
pressed genes were not changed by addition of RA. This
was somewhat unexpected as RARa is an RA activated
nuclear receptor. In contrast, the microarray analyses
identiﬁed several known RA-inducible target genes
(Cyp26a1, Hoxa5, Cdx1, Tmtc1, Csn3, Aurkc, MP11,
Pdgfrb, RARb2, Hoxb5 and Hoxb2 (Supplementary
Data)) as showing >3-fold increases in transcript levels
upon addition of RA to F9 Wt cells for 8h.
We validated four of the RA responsive genes
(Cyp26a1, Hoxa5, Hoxb5 and Hoxb2) by real-time
PCR, and demonstrated a similar induction of these
genes in F9 Wt and RARa
 /  cells upon addition of
RA to F9 Wt cells for 8h and for 24h (Figure 1E). This
demonstrates a functional transcriptional response to the
RA treatment, possibly mediated by RARb and/or
RARg. Thus, in the F9 RARa
 /  cells the addition of
RA induces transcription of several known RA responsive
genes. Speciﬁcally, the transcript levels of Cyp26a1,
Hoxa5, Hoxb5 and Hoxb2 were increased by 10-fold or
more while transcript levels of Mest, Tex13, Slc38a4 and
Stmn2 were increased by <2-fold upon 24h of RA treat-
ment of F9 Wt and RARa
 /  cells (Figure 1A and C).
Overall, these results indicate that in F9 Wt cells, but not
in RARa
 /  cells, the levels of several transcripts,
including Mest, Tex13, Slc38a4 and Stmn2, are main-
tained in an RA-independent manner.
The epigenetic signatures of Mest, Tex13, Slc38a4, and
Stmn2 promoters are altered in RARa knockout cells
The largest differences in transcript levels between the Wt
and RARa
 /  cells were observed for Slc38a4 and Mest
(>10-fold difference in RARa
 /  versus Wt cells). These
genes are both paternally expressed (36,43), which
suggests that transcription of Slc38a4 and Mest, and
possibly also of Stmn2 and Tex13 are regulated by differ-
ential CpG promoter methylation in Wt versus RARa
 / 
cells. We identiﬁed CpG-rich promoter regions and
assessed the promoter-speciﬁc methylation status of
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are speciﬁed in Figure 2C (Supplementary Data)).
Because the Mest, Tex13, Slc38a4 and Stmn2 transcript
levels are not affected by RA treatment (Figure 1A and
C), we assessed the methylation status of each of these
genes in untreated F9 Wt and RARa
 /  cells.
The methylation analysis revealed increased CpG
methylation of the Mest and Tex13 promoter regions in
F9 RARa
 /  cells, from  60% for either gene in Wt cells
to 80% in RARa
 /  cells (Figure 2A). Notably, two CpGs
of the Mest promoter region ( 32 and  149) persistently
show low levels of methylation, even in RARa
 /  cells.
The increased promoter methylation correlates with the
decreased Mest and Tex13 transcript levels in RARa
 / 
cells (Figure 1C). The increased promoter methylation in
the RARa
 /  cells supports the idea of a cellular memory,
through increased DNA methylation, by which de novo
methylation is maintained through subsequent cell div-
isions. Conversely, methylation of the Slc38a4 and
Stmn2 promoters is decreased in F9 RARa
 /  cells from
 90% for both genes in Wt to 40% in RARa
 /  cells
(Figure 2A). In summary, the knockout of F9 RARa
results in increased Mest and Tex13 promoter methylation
and decreased Slc38a4 and Stmn2 promoter methylation,
each of which is correlated with altered transcript levels in
RARa
 /  relative to F9 Wt cells (Figures 1A, C and 2A).
In contrast, the Cyp26a1 promoter region was
unmethylated even when transcriptionally silent, i.e. in
the absence of RA [data not shown and (31)]
We wanted to elucidate the underlying mechanisms of
RA-independent transcriptional regulation by RARa by
measuring key histone marks that characterize the
Figure 2. The Epigenetic Signatures of Mest, Tex13, Stmn2 and Slc38a4 promoter regions. (A) Mest and Tex13 promoters displayed increased
methylation in RARa
 /  relative to Wt cells. In contrast, Slc38a4 and Stmn2 displayed decreased methylation in RARa
 /  relative to Wt cells. Each
horizontal line represents the methylation status of an independent allele. The numbers below the ﬁgures indicate the CpG position relative to the
transcriptional start site (+1). (B–D) Promoter speciﬁc ChIP were quantiﬁed by real-time PCR on chromatin IPed from Wt and from RARa
knockout cells treated with vehicle or RA (vehicle—0h; gray and RA—24h; dark gray bars). (B) Histone modiﬁcation in F9 Wt and RARa
 / 
cells. H3K9/14ac modiﬁcations (upper panel). In RARa
 /  cells H3K9/K14ac levels at the Mest and Tex13 promoters is decreased, while levels at
the Stmn2 and Slc38a4 promoters is increased relative to Wt. (C) H3K9me3 modiﬁcations (middle panel). In RARa
 /  cells the H3K9me3 level at
the Mest promoter is increased, while the level at the Slc38a4 promoter is decreased. H3K9me3 levels at the Tex13 and Stmn2 promoters are not
signiﬁcantly changed in RARa
 /  cells. A low signal (15- to 30-fold above the IgG) for H3K9me3 is seen at the Cyp26a1 promoter. (D) H3K4me3
modiﬁcations (lower panel). In RARa
 /  cells H3K4me3 levels at the Mest and Tex13 promoters are decreased, whereas the levels at the Stmn2 and
Slc38a4 promoters are increased relative to Wt. The signal from the IgG IP was set to 1 for each PCR. The data represent three independent IPs for
each Ab, harvesting new chromatin for each IP. Statistical signiﬁcance is demonstrated by P-values below 0.05 for the indicated comparisons.
(C) Mest proximal promoter region. The promoter (excluding the sequences in italics) was evaluated for CpG methylation (bold). Underlined
sequences indicate putative elements: RARE (DR1), NFkB-binding site, TATA box (TATA), transcriptional start site (TSS) and the exact region
targeted by ChIP primers (labels to the right).
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Stmn2 promoter regions. Speciﬁcally, we assessed the
H3K9/K14ac, H3K9me3 and H3K4me3 marks on the
Mest, Tex13, Slc38a4 and Stmn2 promoters in the Wt
and RARa
 /  cell lines by chromatin immunopre-
cipitation (ChIP). In addition, the histone marks on the
RA inducible Cyp26a1 promoter (Figure 1E) were
assessed as a control (Mest, Tex13, Stmn2, Slc28a4 and
Cyp26a1 ChIP target regions (Supplementary Data)).
The H3K9/K14ac levels at the Mest and Tex13 pro-
moters decreased, while levels at the Stmn2 and Slc38a4
promoters increased in RARa
 /  relative to Wt
(Figure 2B, upper panel). Increased H3K9/K14ac levels
at the Cyp26a1 promoter in RA-treated cells corroborate
transcriptional activation by RA in Wt and in RARa
 / 
cells (Figures 1D and 2B). We also found that the
H3K9me3 levels at the Mest promoter increased, while
levels at the Slc38a4 promoter decreased in RARa
 / 
relative to Wt cells (Figure 2B, middle panel). H3K9me3
levels displayed no changes at the Tex13 and Stmn2 pro-
moters in F9 RARa
 /  relative to Wt cells (Figure 2B,
middle panel). The H3K4me3 levels at the Mest and Tex13
promoters decreased in RARa
 /  relative to Wt cells
(Figure 2B, lower panel), while levels at the Stmn2 and
Slc38a4 promoters increased relative to Wt cells
(Figure 2B, lower panel). Increased H3K4me3 levels at
the Cyp26a1 promoter in RA-treated cells further corrob-
orate transcriptional activation by RA (Figure 2B, lower
panel). Consequently, the changes in DNA methylation in
the Mest, Tex13, Slc38a4 and Stmn2 promoter regions
upon knockout of RARa correlate with changes in
histone marks associated with the respective promoters.
Importantly, these speciﬁc changes in epigenetic signatures
also correlate with speciﬁc changes in Mest, Tex13,
Slc38a4 and Stmn2 transcript levels in RARa
 /  cells
relative to Wt cells.
RARa and RXRa associate with the Mest, but not the
Tex13, Slc38a4, and Stmn2 promoters
We next wanted to determine if Mest, Tex13, Slc38a4 and
Stmn2 are direct targets of RARa, we performed ChIP
using an RARa antibody and measured the enrichment
of Mest, Tex13, Slc38a4 and Stmn2 promoters in
chromatin immunoprecipitated from Wt relative to that
from RARa
 /  cells. In order to assess RARa hetero-
dimerization with RXRa we performed parallel ChIP
assays using an RXRa antibody (Supplementary Data).
We identiﬁed RARa at the Mest promoter (>2-fold in
both untreated and RA-treated Wt cells relative to
RARa
 /  cells, P<0.05), but not at the Tex13, Stmn2
and Slc38a4 promoter regions (each <2-fold enrichment,
P>0.05). This suggests that only the Mest promoter is a
direct target of RARa (Figure 3A). In contrast, RARa
levels at the Cyp26a1 promoter increased upon RA treat-
ment in Wt cells (>2-fold, P<0.05), but not in RARa
 / 
cells (P>0.05). However, the transcription of Cyp26a1 is
not dependent on RARa since similar Cyp26a1 transcript
levels are observed in Wt and RARa
 /  cells after RA
addition (Figure 1E), which is consistent also with tran-
scription of Cyp26a1 relying primarily RARg (29).
We conclude that RARa is associated with the Mest
promoter, but not with Tex13, Stmn2, and Slc38a4 pro-
moters. In support of our ﬁndings a genome-wide
mapping of RARa-binding sites in MCF-7 breast cancer
cells demonstrated binding of RARa proximal to the Mest
promoter, but not to the Tex13, Stmn2 and Slc38a4 pro-
moters (12).
We identiﬁed RXRa at the Mest promoter only in Wt
cells (>2-fold relative to RARa
 /  cells, P<0.05), but not
at the Tex13, Stmn2 and Slc38a4 promoters (each <2-fold
enrichment, P>0.05). This suggests that only the Mest
promoter is a direct target of RXRa (Figure 3B). In
contrast, we detected an RA dependent increase in
RXRa at the Cyp26a1 promoter in Wt and in RARa
 / 
cells (evident by a >2-fold higher signal in Wt and
RARa
 /  cells after RA, P=0.01 and 0.03, respectively).
The minor RA dependent increase in RXRa levels at the
Cyp26a1 promoter even in RARa
 /  ( 2-fold) suggests
that RARb and/or RARg are partners of RXRa at the
Cyp26a1 promoter, thus corroborating the role of RARg
in the regulation of Cyp26a1 (30). The assays demonstrate
that RXRa is associated with the Mest promoter only in
Wt cells, e.g. only in the presence of RARa. The reported
heterodimerization of RARa and RXRa (56) corrobor-
ates the requirement of RXRa on RARa for association
with the Mest promoter. We conclude that direct binding
of RARa/RXRa heterodimers is required to maintain
RA-independent transcription of the Mest gene
(Figure 5B).
Ectopic expression of RARa2 in F9 RARa
 /  cells
partially restores Mest transcript levels
To conﬁrm that the altered transcriptional activity
observed in RARa
 /  cells relative to Wt cells is indeed
caused by the loss of RARa we re-introduced RARa2,
which in F9 cells is the predominantly expressed isoform
originating from the RARa gene. We derived two inde-
pendent cell lines from the F9 RARa
 /  cell line (RARa
 / 
:RARa2, clone #1 and clone #2), which stably express
murine RARa2 in the RARa null background
(Supplementary Data)). We then assessed Mest, Stmn2,
Tex13 and Slc38a4 transcript levels in each of the two
RARa2 restoration cell lines.
We observed increased Mest transcript levels in both
RARa2 restoration cell lines relative to the parent F9
RARa
 /  cell line (Figure 4A, upper left, P<0.01). The
RARa2 transcript levels in each of the RARa2 restoration
cell lines were below the RARa transcript levels seen in Wt
(67% and 50%, respectively), but still signiﬁcantly higher
than in the RARa
 /  cells (Figure 4A, upper right,
P<0.01). The overall Mest promoter methylation was
not reversed by restoring RARa2 expression (Figure 4A,
lower right), but in contrast to both Wt and RARa
knockout cells, speciﬁc CpG sites ( 155,  124 and  32)
displayed extremely low levels of methylation. Stmn2 tran-
script levels were reduced in both RARa2 restoration cell
lines relative to the parent F9 RARa
 /  cell line
(Figure 4A, upper middle). The Tex13 and Slc38a4 tran-
script levels were inconsistent between the two RARa2
restoration cell lines (Figure 4A, lower).
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transcript levels in the RARa
 /  cell lines are related to
the lack of RARa. Furthermore, our observation that
Mest and Stmn2 transcript levels are only partially
restored upon RARa2 restoration in RARa
 /  cells
(Figure 4A, upper left), suggests that this RARa
 / 
phenotype is not fully reversible.
Expression of the PML–RARa oncogene alters transcript
levels of Mest, a direct RARa target gene
APL is frequently caused by a t(15;17) (q22;q12–21) trans-
location which introduces the expression of an oncogenic
PML–RARa fusion protein (2,57). Several reports suggest
that oncogenic RARa fusion proteins cause APL in part
by functioning as a dominant negative RAR (4,58,59). We
hypothesized that the oncogenic PML–RARa fusion
protein would function as a dominant negative regulatory
protein, effectively preventing RARa (and possibly RARb
and RARg) from functioning in F9 Wt cells. If our hy-
pothesis is correct, genes such as Mest, whose expression is
maintained by RARa, would be silenced upon expression
of the PML–RARa oncoprotein in F9 Wt cells. In
addition, if the phenotype from overexpression of the
dominant negative PML–RARa in F9 Wt cells mimics
the phenotype of RARa knockout cells, this would be
validation of the role of RARa in RA-independent tran-
scriptional regulation.
In order to test this hypothesis, we generated an F9 cell
line, PML–RARa
+(Wt), which stably expresses a murine
PML–RARa fusion protein in the wild-type background
(the 562 amino-terminal residues of PML fused to 400
carboxy-terminal residues of RARa (Supplementary
Data)). We then assessed Mest, Tex13, Slc38a4 and
Stmn2 transcript levels in the PML–RARa
+(Wt) cells.
Since oncogenic RARa fusion proteins attenuate the RA
responsiveness of HL-60 and U937 cells (4,59), the tran-
scriptional induction of Cyp26a1 by RA treatment of the
F9 PML–RARa
+(Wt) cells was assessed in parallel.
We observed reduced levels of Mest transcript and
increased levels of promoter methylation in the F9
PML–RARa
+(Wt) relative to F9 Wt cells (Figure 4B).
In contrast, Tex13 expression was elevated by  20% in
PML–RARa
+(Wt) compared to Wt cells (Figure 4B).
Only minor changes in Slc38a4 and Stmn2 transcript
levels were observed in PML–RARa
+(Wt) relative to Wt
cells (Figure 4B). Consequently, expression of the PML–
RARa fusion protein in F9 Wt cells recapitulated the
RARa
 /  phenotype with respect to Mest, but not with
respect to Tex13, Slc38a4 and Stmn2 transcript levels.
Figure 3. RARa and RXRa binding to target promoters. Promoter speciﬁc ChIP were quantiﬁed by real-time PCR on chromatin IPed from Wt and
from RARa
 /  cells treated with vehicle or RA (vehicle–0h; gray and RA–24h; dark gray bars). The chromatin was IPed using (A) an RARa Ab,
(B) an RXRa Ab or (C) IgG negative control. The western blot in Figure 1f demonstrates antibody speciﬁcity toward RARa. The average signal
from IgG IP was set to 1 (marked by the light gray background in A, B and C). The data represent four independent IPs for each Ab, harvesting new
chromatin for each IP. Statistical signiﬁcance is demonstrated by P<0.05 for the indicated comparisons.
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in the PML–RARa
+(Wt) cells relative to Wt cells after
24h of RA (Figure 4B), the RA responsiveness of the
Cyp26a1 gene was greatly attenuated upon overexpression
of PML–RARa. In summary, whereas the knockout of
RARa was associated with decreased Mest and Tex13
transcript levels and increased Slc38a4 and Stmn2 tran-
script levels, only Mest transcript levels were decreased
upon overexpression of a PML–RARa fusion protein in
F9 Wt cells. Consequently, stably expressing the PML–
RARa protein in F9 Wt cell recapitulate the RARa
knockout phenotype with respect to the Mest transcript
levels and promoter methylation.
DISCUSSION
Transcriptional silencing through DNA methylation has
been extensively studied, yet the reverse process of tran-
scriptional activation through DNA demethylation has
started to receive attention only in recent years. We have
demonstrated that knockout of RARa is accompanied by
increased methylation of the Mest and Tex13 promoter
Figure 4. Ectopic RARa expression affects Mest transcript levels in F9 cells. (A) Full-length RARa2 was stably expressed in F9 RARa
 /  cells
(upper right). Transcript levels assessed by real-time PCR demonstrate partial restoration of Mest transcript levels (upper left), but no reversal of the
overall promoter methylation (lower left). Stmn2 transcript levels were not affected (middle panel). Tex13 and Slc38a4 transcript levels were
inconsistent between the two independent RARa2 restoration lines (lower middle and right panel). The P-values show a comparison of RARa2
restoration cell lines to the RARa knockout cell line. The data represent three independent assays, harvesting new RNA for each experiment. (B) The
PML–RARa oncogene was stably expressed in F9 Wt cells. Transcript levels assessed by real-time PCR (upper left panel) suggest a dominant
negative function of the PML–RARa protein for Mest associated with increased levels of promoter methylation (lower left panel), while Tex13,
Slc38a4 and Stmn2 transcript levels were not affected (Wt, 24h RA was set to 1). RA induced transcription of Cyp26a1 was impaired in PML–
RARa expressing cells (upper right panel). The duration of the RA treatment is indicated by the bar color (0h; gray, 8h; light gray, and 24h; dark
gray bars). The P-values show a comparison of the PML–RARa cell line to the F9 Wt cells. The data represent three independent assays, harvesting
new RNA for each experiment.
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Stmn2 promoter regions, an effect that, with respect to
Mest and Stmn2 transcript levels, is partially reverted
upon restoration of RARa2 expression in RARa
 / 
cells. Furthermore, with respect to Mest the RARa
 / 
phenotype is recapitulated by overexpression of PML–
RARa in F9 Wt cells.
In RARa
 /  cells both Mest and Tex13 overall
promoter methylation was increased from 60% to 80%.
However, whereas Mest transcript levels and H3K9/
K14ac levels were severely reduced (to 13% and 15%,
 /+ RA, respectively), the Tex13 transcript levels and
H3K9/K14ac levels were only moderately reduced (to
49% and 48%,  /+ RA, respectively). Consequently,
promoter methylation only partially reﬂects the transcrip-
tional activity. The H3K9me3 repressive histone mark
displays a much stronger association with the Mest
promoter region than with the Tex13 promoter region,
which may account for the more pronounced repression
of Mest relative to Tex13 in RARa
 /  cells. Overall, the
altered levels of promoter methylation correlate with
speciﬁc changes in histone modiﬁcations (H3K9me3,
H3K9/K14ac and H3K4me3). The RA-independent asso-
ciation of RARa and RXRa with the Mest promoter
region contrasts with the RA dependent enrichment of
RXRa at the Cyp26a1 promoter region and points to a
direct role of RARa/RXRa heterodimers in preventing
DNA methylation of the Mest promoter region of Wt
cells. Our data also suggest that the lower level of DNA
methylation of the Tex13 promoter region and the highly
methylated states of the Slc38a4 and Stmn2 promoter
regions are indirectly maintained by RARa in F9 Wt
cells (Figure 5B). However, we cannot exclude the possi-
bility that distant RARa-binding sites regulate Tex13,
Stmn2 and Slc38a4 expression, as these would elude de-
tection in the promoter speciﬁc ChIP assay.
A novel ligand-independent function of RARa
Retinoid receptors and other nuclear hormone receptors
has been reported to regulate transcription mainly by their
ability to activate and repress transcriptional activities re-
versibly in the presence and absence of ligands, respect-
ively (30,31,60–62). We identiﬁed several transcripts,
including Mest, Tex13, Slc38a4 and Stmn2, which are dif-
ferentially expressed between F9 Wt and RARa
 /  cells in
a RA-independent manner, e.g. the exogenous addition of
RA had no effect on the transcriptional activities
measured by transcript levels (Figure 1), promoter methy-
lation and histone modiﬁcations (Figure 2). We cannot
rule out that these differences are caused by endogenously
produced ligands, but a number of ﬁndings argue for an
unliganded function of RARa. First, several known RA
responsive genes, including Hoxb5, Hoxa5, Cyp26a1 and
Hoxb2, were potently induced in F9 Wt and in RARa
 / 
cells upon RA addition (Figure 1E), thus demonstrating a
positive transcriptional effect of RA in the RARa
 /  cells.
Second, RARa has been shown by us and others to
mediate RA-dependent transcription of reporter
plasmids (63,64), and thus to have the capability to
mediate ligand-dependent transcriptional activation.
Third, using a non-biased, genome-wide approach,
RARa-binding sites have been identiﬁed proximal to
both RA responsive and RA non-responsive genes
(11,12), and it was suggested that RA responsiveness
may be dictated by the speciﬁc conﬁguration of the
RARE. In this respect, it is particularly intriguing that
the Mest promoter contains a degenerate RARE immedi-
ately downstream of the ChIP target region (Figure 2C).
Our ﬁndings demonstrate that in F9 cells the levels of
RARa and RXRa at the Mest promoter region were not
affected by the presence of RA, since the IP signals dis-
played no statistically signiﬁcant change upon RA treat-
ment of Wt cells [p(RARa)=0.28 and p(RXRa)=0.72,
respectively, Figure 3]. This suggests that RARa/RXRa
heterodimers can maintain transcription of Mest inde-
pendently of RA. In contrast, the levels of RARa and
RXRa at the Cyp26a1 promoter region increased upon
RA treatment of Wt cells [p(RARa)=0.04 and
Figure 5. Model for RARa dependent epigenetic regulation.
(A) Ligand-independent binding of RARa/RXRa heterodimers to the
Mest promoter region is required to maintain transcriptionally permis-
sive histone modiﬁcations (H3K4me3 and H3K9/K14ac) and relatively
low methylation levels of promoter CpG islands (upper panel).
Knockout of RARa results in higher levels of Mest promoter methy-
lation, loss of permissive histone modiﬁcations, and gain of repressive
histone modiﬁcations (lower panel). (B) Actively transcribed genes
display relative low levels of promoter methylation and high levels of
H3K9/K14ac and H3K4me3 (Mest and Tex13 in Wt, Stmn2 and
Slc38a4 in RARa
 / ), whereas silenced genes display high levels of
promoter methylation and, if paternally expressed, high H3K9me3
levels (Slc38a4 in Wt, Mest in RARa
 / ). Transcriptional start sites
(TSS) and relative transcriptional activities are indicated by the arrows
and arrow sizes, respectively. The relative levels of CpG promoter
methylation are denoted by black lollipops (the CpG-rich regions
assessed each span the TSS but for clarity are drawn upstream of the
TSS).
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suggest that RA treatment results in increased levels of
RARa (and RXRa) at RA responsive elements (as
observed for the promoter proximal RARE of
Cyp26a1), whereas RARa targets whose transcriptional
activities are independent of ligand binding (e.g. Mest)
do not display changes in the levels of RARa (and
RXRa) upon RA treatment (Figure 5A). Intriguingly,
the model of RARs and RXRs constitutively associated
with RAREs even in the absence of ligand was recently
challenged by a study which demonstrated a highly
dynamic and RA-dependent association of RARs and
RXRs with endogenous RAREs (65). It is worth noting
that the Mest promoter contains a degenerate putative
RARE (DR1), whereas the Cyp26a1 promoter contains
two proximal RAREs (DR5), thus potentially explaining
why RA induces transcription of Cyp26a1 but not of
Mest. Alternatively, cis-bound transcription factors may
modulate the function of RARa. In this respect, the rela-
tively low levels of methylation of the two CpGs in the
Mest promoter, even in the RARa
 /  cells, may indicate
the presence of constitutively bound transcription factors.
A putative NFkB-binding site (GGRNNYYCC) located
next to CpG( 149) and a potential TATA-box positioned
proximal to CpG ( 32) may indicate coordinated action
of several transcription factors. Upon restoration of
RARa2 expression it is interesting that CpG ( 32)
becomes unmethylated. In contrast, the CpG ( 149) is
highly methylated, but the two neighboring sites to CpG
( 149) exhibit low levels of DNA methylation. In
summary, the Mest transcript levels are partially rescued
by restored RARa2 expression. However, the promoter
methylation is reversed only for speciﬁc sites. This
suggests that these sites may be key in regulating the tran-
scriptional activity of Mest.
Expression of PML–RARa in F9 Wt cells mimics the
aberrant Mest transcription in RARa knockout cells
The Mest and Cyp26a1 transcript levels were differentially
affected by the expression of PML–RARa in F9 Wt cells
(Figure 4B). The transcriptional induction of Cyp26a1 by
RA was attenuated in PML–RARa
+(Wt) but not in
RARa
 /  cells. In contrast, Mest expression was
reduced in both PML–RARa
+(Wt) and in RARa
 / 
cells relative to Wt cells (Figure 4B). Whereas transcrip-
tion of Cyp26a1 is regulated by ligand binding to RARb
and/or RARg (29), the transcription of Mest shows a
strong correlation with promoter methylation and
presence of RARa/RXRa dimers in the proximal
promoter region. Consequently, the expression of PML–
RARa and the knockout of RARa have similar effects on
Mest expression, but different effects on Cyp26a1 expres-
sion. The ligand-independent association of RARa only
with the Mest promoter (Figure 3) may explain why the
introduction of PML–RARa mimicked the loss of RARa
only for the Mest gene, and not for Tex13, Slc38a4 and
Stmn2. We suggest that PML–RARa expression attenu-
ates transcription from RA-inducible promoters (e.g.
Cyp26a1) as previously reported, but functionally
mimics the lack of RARa at RARa target promoters,
which are not RA responsive (e.g. Mest).
Association with RARa maintains high transcriptional
activity and low levels of promoter methylation
When comparing the set of genes with aberrant transcript
levels in RARa knockout cells with the genomic RARa
targets identiﬁed in a genome-wide study evaluating DNA
binding of RARa in MCF-7 cells (12), an intriguing
pattern emerges. The RARa-binding sites identiﬁed by
Hua et al. mapped exclusively to promoter regions of
genes whose transcript levels were decreased in the F9
RARa knockout cells (Mest, Tcfap2a, Cux1, HMGcs1
and Gab1, Figure 1A and B (Supplementary Data)).
None of the more than 7000 RARa-binding sites identiﬁed
(12) mapped to genes with transcript levels elevated in the
F9 RARa knockout cells (relative to F9 Wt cells), which
indicates that target genes directly regulated by RARa
display decreased expression in the absence of RARa.
We observed direct association of RARa with the Mest
promoter in Wt cells, and increased promoter methylation
of Mest in RARa knockout cells, which suggests that
RARa through direct association can hinder CpG methy-
lation of speciﬁc promoters. Mixed-lineage leukemia
(MLL) which is a H3K4 methyltransferase of the
Trithorax family maintains transcription by preventing
of CpG methylation in the Hoxa9 promoter regions of
murine embryonic ﬁbroblasts (66). The decreased
H3K4me3 association with the Mest promoter region in
RARa
 /  cells (Figure 2B, lower panel) argues that the
H3K4 methyltransferase activity of MLL plays an import-
ant role in the epigenetic regulation of Mest and possibly
other genes whose expression is reduced in RARa
 /  cells.
Intriguingly, RARa has been reported to interact directly
with MLL5, a key MLL in hematopoiesis (67,68). This
provides a biologically relevant, potential mechanism for
the methylation inhibitory function of RARa.
The function of RARa may be modulated by TIF1b
The notion that Mest transcriptional activity is main-
tained by RARa/RXRa heterodimers poses the intriguing
question of why Mest is not induced by RA treatment. It
has been suggested that binding of RAR/RXR
heterodimers is required, but not sufﬁcient for RA respon-
siveness (11). Indeed, this model is consistent with the
observed RARa binding to genomic elements devoid of
RA responsive genes (12). Alternatively, the lack of RA
responsiveness could result from the activities of
co-repressors (e.g. Sin3a, N-CoR2 or TIF1b) which
modulate the activity of RARa. In manipulated F9 cells,
heterozygotic for TIF1b, the expression of Mest was RA
inducible (69), suggesting that the activity of RARa can be
modulated by TIF1b. Another candidate is the PRAME
co-repressor, which can bind to RARs in the presence of
RA and prevent ligand-induced transcriptional activation
(70), potentially by inhibiting RARa. However,
ectopically expressed PRAME and RARa both caused
resistance to growth arrest and apoptosis induced by
HDAC inhibitors (71), which indicate similar, not
112 Nucleic Acids Research, 2012,Vol. 40,No. 1opposing functions of ectopically expressed PRAME and
RARa.
Alternatively, RARE conﬁguration was suggested to
determine RA responsiveness (11), but may be further
modulated by promoter speciﬁc epigenetic signatures.
Indeed, the increased levels of RARa at the RA inducible
Cyp26a1 promoter versus the unchanged levels of RARa
at the RA non-responsive Mest promoter (Figure 3)
indicate that the promoter epigenetic signature play a
role in determining the RAR association and thus RA
responsiveness. This is supported by histone modiﬁcations
and transcript levels, which demonstrate that the Mest
gene is transcriptionally active in the absence of RA
(Figure 1C), whereas Cyp26a1 is silent in the absence of
RA (Figure 1E).
The biological relevance of RARa regulated imprinting
The majority of genes whose transcript levels differ
between the Wt and RARa
 /  cell lines are expressed in
the placenta, the testis and the brain (Supplementary
Data). These tissues are all sites where imprinting plays
a major role in transcriptional regulation (54,55), and im-
portantly, RARa is expressed in these speciﬁc tissues
(72–74). We predict that RARa plays a key role in
regulating genetic imprinting in animals, but this has yet
to be investigated.
It was recently demonstrated that in the growth plate, a
cartilage structure located between the epiphysis and
metaphysis of long bones, differentiation from stem-like
to hypertrophic chondrocytes is associated with decreased
Mest expression and increased Slc38a4 expression (75).
This inverse correlation corroborates our ﬁndings and
provides a physiological framework for the molecular
mechanisms identiﬁed here. Based on the key role of
RARa in hematopoiesis (1) and the interaction of
RARa with MLL5 (67), we speculate that similar
changes in Mest and Slc38a4 expression occur during
the differentiation of hematopoietic stem cells and that
these changes in transcriptional activities are associated
with the same epigenenetic changes in DNA and
histones as here reported. The ligand-independent
mechanism of RARa identiﬁed here sheds new light on
the mechanisms of RA receptor action, and suggests
that in addition to ligand-induced transcriptional
regulation, ligand-independent regulation should be con-
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